Pfizer eyes $7.3bn takeover of weight-loss drug developer Metsera

The deal marks Pfizer's latest bid to secure a foothold in the lucrative anti-obesity drug market

Pfizer is closing in on a potential $7.3bn (€6.22bn) takeover of weight-loss drug developer Metsera. Pfizer employs more than 4,000 people in Ireland Picture: Dan Linehan

Pfizer is closing in on a potential $7.3bn (€6.22bn) takeover of weight-loss drug developer Metsera, the Financial Times has reported, citing unidentified sources.

The US pharma firm will acquire New York City-based Metsera for $47.50 per share in cash, with an additional $22.50 per share contingent on the achievement of certain performance milestones, the newspaper said, adding that the announcement could come as early as Monday, unless deal talks fall through.